# Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax)

> **NCT03066986** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Central Adelaide Local Health Network Incorporated** · enrollment: 40 (actual)

## Conditions studied

- Ant Sting
- Immunotherapy

## Interventions

- **DRUG:** Delta-inulin
- **BIOLOGICAL:** Dose finding comparison

## Key facts

- **NCT ID:** NCT03066986
- **Lead sponsor:** Central Adelaide Local Health Network Incorporated
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03066986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03066986, "Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03066986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*